This is a transcript from the meeting:
Sarah Dash: Good afternoon, everybody. Welcome. I am Sarah Dash. I’m co-CEO of the Alliance for Health Reform and, since this is the first briefing I’m moderating in my new role, I want to recognize my partner in crime and other co-CEO who is Marilyn Serafini, and I also want to wish the best to Ed Howard who, as many of you know, led the Alliance for nearly 25 years before he retired last month.
So, just as a reminder, to those of you who might be new to us today, the Alliance for Health Reform is a nonpartisan, nonprofit organization that is aimed at health policy education. We don’t lobby on any issues, although it is our hope that by opening discussing the tough issues in a balanced way, we will do some good in helping policy makers and others move towards a higher quality, more affordable healthcare system.
Today has been a busy day already. I know that it is Emancipation Day in the district and hopefully your taxes are done already because we are about to buckle down and get to a really interesting and tough issue, and that is drug prices. And I also want to thank CVS Health for their support of this important conversation.
So you can join the conversation on Twitter using the hashtag drug prices, and we’re here today with a really fabulous panel to talk about what value might mean when it comes to prescription medicines, how that value is assessed, and how it fits in with overall healthcare payment and delivery. And we know that on Monday of this week, the Alliance started off with a briefing on delivery system reform and what we know about alternative payment models and so forth, so perhaps it’s fitting that we’re ending the week talking about how prescription medicines might fit into that conversation.
So within these so-called value frameworks, or value models, have been garnering a lot of attention and today we’re going to hear about the data and considerations that go into the value equation, what might be missing, and where we go from here.